This analysis also identified ID3-independent receptors, including the activating receptor LRP1, which binds to tumour-expressed calreticulin18 and the inhibitory receptor SIGLECG (also known as SIGLEC10), which binds to CD24 on tumour cells7, which were expressed in Id3-deficient and control KCs (Extended Data Figs. 3c and 6b). The gene discussed is SIGLEC10; the disease is neoplasm.